What is the reason to delay launching the SGLT-2 inhibitor type diabetes treatment?
Boehringer Ingelheim and Lilly decided to delay launching the diabetes treatment ‘Jardiance’ in the market.
According to the industry concerned on the 15th, Boehringer Ingelheim and Lilly (hereinafter referring to BI·Lilly) has halted on the launching procedure of the SGLT-2 inhibitor ‘Jardiance...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
